Valiant Laboratories' Q2 FY 2025-26 Quarterly Results

Result Summary

• Valiant Laboratories Ltd reported a 0.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 89.5%.
• Its expenses for the quarter were up by 3.9% QoQ and 62.7% YoY.
• The net profit decreased 89.0% QoQ and decreased 104.2% YoY.
• The earnings per share (EPS) of Valiant Laboratories Ltd stood at 0.04 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Valiant Laboratories Ltd is a company whose primary operations and business activities are not detailed in the provided data. Therefore, specific information about its main products or services, industry sector, and any recent major developments within the company are not available. Further research would be required to accurately outline the company's operational landscape and strategic initiatives, as well as any industry-specific factors that may influence its performance. As of the current analysis, only the financial data has been provided, without context regarding the company's position in the market or any external factors that could affect its operations.

Revenue

For the second quarter of the fiscal year 2026 (Q2FY26), Valiant Laboratories Ltd reported a total income of ₹47.07 crores. This represents a slight decrease of 0.9% from the previous quarter (Q1FY26), where the total income was ₹47.48 crores. However, when compared to the same quarter in the previous fiscal year (Q2FY25), the total income shows a significant increase of 89.5%, rising from ₹24.84 crores. The year-over-year growth in total income suggests an increase in revenue generation capabilities or possibly an expansion in business operations compared to the previous year, though specific reasons for this growth are not detailed in the available data.

Profitability

The profitability metrics for Valiant Laboratories Ltd in Q2FY26 indicate a challenging situation. The company reported a profit before tax of ₹0.28 crores, which is markedly lower than the ₹2.45 crores reported in Q1FY26, reflecting a quarter-over-quarter decline of 88.6%. Compared to Q2FY25, where a loss before tax of ₹3.91 crores was recorded, there is a year-over-year improvement of 107.2%. Similarly, profit after tax for Q2FY26 was ₹0.20 crores, down by 89.0% from ₹1.82 crores in Q1FY26, yet showing a turnaround from a loss of ₹4.74 crores in Q2FY25, marking a YoY change of 104.2%. These figures highlight significant fluctuations in the company's profitability over the quarters and the year.

Operating Metrics

Operating expenses for Valiant Laboratories Ltd in Q2FY26 amounted to ₹46.79 crores, which is an increase of 3.9% from ₹45.02 crores in Q1FY26. When compared to Q2FY25, where expenses were ₹28.75 crores, the current quarter's expenses have increased by 62.7%. This rise in expenses could be indicative of increased operational activities or higher costs associated with maintaining or expanding business operations. Earnings per share for Q2FY26 were reported at ₹0.04, a decline of 90.5% from ₹0.42 in Q1FY26, but an improvement when compared to a negative EPS of ₹-1.09 in Q2FY25. The tax expense for Q2FY26 was ₹0.08 crores, down from ₹0.63 crores in Q1FY26, and lower than the ₹0.83 crores paid in Q2FY25, indicating significant variability in tax obligations across periods.